Muscle-Specific Nucleic Acid Regulatory Elements for Lower-Dose AAV Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for muscle disorders, particularly Limb Girdle Muscular Dystrophy Type 2E (LGMD2E), face inefficiencies in gene delivery and expression in skeletal muscles, heart, and diaphragm, and are hindered by immune responses and toxicity from high vector doses.
Innovation Solution
Development of novel combinations of transcriptional cis-regulatory elements (CREs) to enhance muscle-specific gene expression, using AAV vectors with diaphragm- and heart/skeletal muscle-specific regulatory elements, allowing for high and tissue-specific expression of therapeutic proteins like β-sarcoglycan at lower, safer vector doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high vector doses are used to achieve desirable therapeutic effect in muscle-directed gene therapy, then gene expression level is improved, but toxicity and immune responses increase
Solution Approach 1:
The patent applies local quality by using tissue-specific regulatory elements (diaphragm-specific and skeletal muscle-specific CREs) to direct gene expression specifically to target muscle tissues. This ensures high therapeutic effect in the intended location while avoiding unnecessary exposure and toxicity in non-target organs, thereby resolving the contradiction between achieving therapeutic effect and minimizing systemic toxicity.
Solution Approach 2:
The patent changes the parameter of vector dose by demonstrating that optimized regulatory elements enable effective gene therapy at lower vector doses. The combination of diaphragm-specific and skeletal muscle-specific CREs increases transgene expression efficiency, allowing reduction of the vector dose from high levels (which cause toxicity) to lower levels (which are safer) while maintaining therapeutic efficacy.
2Reliability
If conventional vectors are used to deliver therapeutic genes to muscle tissues, then gene delivery is achieved, but expression efficiency is insufficient
Solution Approach 1:
The patent uses composite regulatory elements by combining diaphragm-specific CREs and skeletal muscle-specific CREs into a hybrid regulatory structure. This composite approach leverages the strengths of both tissue-specific elements to achieve superior and broader muscle tissue expression compared to using either element alone, thereby resolving the contradiction between reliable gene delivery and sufficient expression efficiency.
Solution Approach 2:
The patent merges diaphragm-specific regulatory elements with skeletal muscle-specific regulatory elements to create a combined regulatory structure. This merging enables the vector to achieve both diaphragm and skeletal muscle expression simultaneously, overcoming the limitation of conventional vectors that fail to achieve sufficient expression efficiency across multiple muscle tissue types.
3Reliability
If muscle-specific regulatory elements are used to enhance gene expression, then tissue-specific expression is improved, but vector dose requirement increases
Solution Approach 1:
The patent applies local quality by using tissue-specific regulatory elements to concentrate gene expression specifically in diaphragm and skeletal muscle tissues. This localized expression strategy increases the effectiveness of each vector particle delivered to target tissues, thereby reducing the overall vector dose required to achieve therapeutic effect compared to non-specific expression patterns.
Solution Approach 2:
The patent changes the parameter of expression efficiency through optimized regulatory elements, which allows reduction of vector dose. The diaphragm-specific and skeletal muscle-specific CREs enhance transgene expression per vector particle, enabling lower vector doses to achieve the same therapeutic effect, thus resolving the contradiction between tissue-specific expression and vector dose requirement.
Data Source
AI summary
Nucleic acid regulatory elements that are able to enhance muscle-specific expression of genes, in particular expression in muscle cells and/or tissues such as in diaphragm, smooth muscle, heart and/or skeletal muscle, including at least two diaphragm-specific regulatory elements and a heart- and skeletal muscle-specific regulatory element. Expression cassettes and vectors containing these nucleic acid regulatory elements, as well as uses thereof such as applications using gene therapy of muscle-related disorders, more particularly diaphragm, heart and/or skeletal muscle-directed gene therapy, and for vaccination purposes.